Added value of [18F]FDOPA PET to the management of high-grade glioma patients after their initial treatment: a prospective multicentre study

• DOI: 10.1007/s00259-023-06225-0
• Publication Date: 2023-04-22T04:02:00Z
• Authors: Jacques Darcourt; David Chardin; Véronique Bourg; Jocelyn Gal; Renaud Schiappa; Marie Blonski; Pierre-Malick Kou...; Fabien Almairac; Lydiane Mondot; Florence Le Jeune; Laurent Collombier; Aurélie Kas; Luc Taillandier; Antoine Verger
• Keywords: Diagnostic efficacy; Patients’ management; Brain Neoplasms; Glioma; Sensitivity and Specificity; 3. Good health; Dihydroxyphenylalanine; Positron-Emission Tomography; High-grade gliomas recurrence; Glioblastoma recurrence; Humans; [SDV.IB]Life Sciences [q-bio]/Bioengineering; Prospective Studies; [18F]FDOPA PET; Radiopharmaceuticals; Neoplasm Recurrence, Local

Diagnostic value of 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine ([18F]FDOPA) PET in patients with suspected recurrent gliomas is recognised. We conducted a multicentre prospective study to assess its added value in the practical management of patients suspected of recurrence of high grade gliomas (HGG).Patients with a proven HGG (WHO grade III and IV) were referred to the multidisciplinary neuro-oncology board (MNOB) during their follow-up after initial standard of care treatment and when MRI findings were not fully conclusive. Each case was discussed in 2 steps. For step 1, a diagnosis and a management proposal were made only based on the clinical and the MRI data. For step 2, the same process was repeated taking the [18F]FDOPA PET results into consideration. A level of confidence for the decisions was assigned to each step. Changes in diagnosis and management induced by [18F]FDOPA PET information were measured. When unchanged, the difference in the confidence of the decisions were assessed. The diagnostic performances of each step were measured.107 patients underwent a total of 138 MNOB assessments. The proposed diagnosis changed between step 1 and step 2 in 37 cases (26.8%) and the proposed management changed in 31 cases (22.5%). When the management did not change, the confidence in the MNOB final decision was increased in 87 cases (81.3%). Step 1 had a sensitivity, specificity and accuracy of 83%, 58% and 66% and step 2, 86%, 64% and 71% respectively.[18F]FDOPA PET adds significant information for the follow-up of HGG patients in clinical practice. When MRI findings are not straightforward, it can change the management for more than 20% of the patients and increases the confidence level of the multidisciplinary board decisions.